Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)’s stock price has increased by 72.25 compared to its previous closing price of 14.65. However, the company has seen a 73.08% increase in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-29 that Deciphera Pharmaceuticals (NASDAQ: DCPH ) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical. This deal has ONO Pharmaceutical acquiring Deciphera Pharmaceuticals for $25.60 per share in cash.
Is It Worth Investing in Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) Right Now?
Additionally, the 36-month beta value for DCPH is 0.40. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for DCPH is 50.23M and currently, short sellers hold a 11.45% ratio of that float. The average trading volume of DCPH on April 29, 2024 was 516.13K shares.
DCPH’s Market Performance
DCPH stock saw an increase of 73.08% in the past week, with a monthly gain of 60.43% and a quarterly increase of 68.80%. The volatility ratio for the week is 4.29%, and the volatility levels for the last 30 days are 4.27% for Deciphera Pharmaceuticals Inc (DCPH). The simple moving average for the last 20 days is 68.45% for DCPH stock, with a simple moving average of 79.29% for the last 200 days.
Analysts’ Opinion of DCPH
Many brokerage firms have already submitted their reports for DCPH stocks, with JP Morgan repeating the rating for DCPH by listing it as a “Neutral.” The predicted price for DCPH in the upcoming period, according to JP Morgan is $14 based on the research report published on November 20, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see DCPH reach a price target of $23. The rating they have provided for DCPH stocks is “Overweight” according to the report published on October 30th, 2023.
Stifel gave a rating of “Buy” to DCPH, setting the target price at $20 in the report published on August 10th of the previous year.
DCPH Trading at 61.80% from the 50-Day Moving Average
After a stumble in the market that brought DCPH to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 42.33% of gains for the given period.
Volatility was left at 4.27%, however, over the last 30 days, the volatility rate increased by 4.29%, as shares surge +59.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +58.35% upper at present.
During the last 5 trading sessions, DCPH rose by +72.91%, which changed the moving average for the period of 200-days by +84.15% in comparison to the 20-day moving average, which settled at $15.45. In addition, Deciphera Pharmaceuticals Inc saw 56.45% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DCPH starting from Kelly Thomas Patrick, who sale 3,010 shares at the price of $15.62 back on Feb 16 ’24. After this action, Kelly Thomas Patrick now owns 80,350 shares of Deciphera Pharmaceuticals Inc, valued at $47,009 using the latest closing price.
Sherman Matthew L, the EVP & Chief Medical Officer of Deciphera Pharmaceuticals Inc, sale 2,615 shares at $15.62 during a trade that took place back on Feb 16 ’24, which means that Sherman Matthew L is holding 108,739 shares at $40,840 based on the most recent closing price.
Stock Fundamentals for DCPH
Current profitability levels for the company are sitting at:
- -1.29 for the present operating margin
- 0.98 for the gross margin
The net margin for Deciphera Pharmaceuticals Inc stands at -1.19. The total capital return value is set at -0.57. Equity return is now at value -56.29, with -42.03 for asset returns.
Based on Deciphera Pharmaceuticals Inc (DCPH), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -5.67. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 57.83.
Currently, EBITDA for the company is -208.86 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 12.33. The receivables turnover for the company is 5.11for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.80.
Conclusion
In conclusion, Deciphera Pharmaceuticals Inc (DCPH) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
